Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying an…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-20
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
News release - English.pdf
News 2026-03-11
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
News release - English.pdf
Results 2026-02-28 Financials
Interim MD&A - English.pdf
Results 2026-02-27 Financials
Interim financial statements/report – English.pdf
News 2025-12-15
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
News release - English.pdf
Results 2025-11-28 Financials
Interim MD&A - English.pdf
Results 2025-11-28 Financials
Interim financial statements/report – English.pdf
News 2025-11-21
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
News release - English.pdf
Results 2025-10-28 Financials
Annual MD&A - English.pdf
Results 2025-10-28 Financials
Audited annual financial statements – English.pdf
News 2025-09-19
News release - English.pdf
News 2025-09-06
News release - English.pdf
News 2025-08-11
News release - English.pdf
News 2025-08-11
Letter from successor auditor.pdf
News 2025-08-11
Letter from former auditor.pdf
News 2025-08-11
Notice.pdf
News 2025-07-31
News release - English.pdf
News 2025-07-08
News release - English.pdf
News 2025-06-26
News release - English.pdf
News 2025-06-04
News release - English.pdf